Skip to main content

Table 1 Eligibility criteria for participants

From: Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial

Inclusion criteria

PCOS as diagnosed by the Rotterdam criteria

BMI ≥ 30 kg/m2

Age 18–45 years

Informed written consent

Exclusion criteria

Patients diagnosed with any known serious chronic illness, including type 1 or 2 diabetes (or a randomly measured fasting plasma glucose > 7 mmol/l)

Angina pectoris, coronary heart disease or congestive heart failure (NYHA Classes III–IV)

Severe renal impairment (creatinine clearance (GFR) < 30 mL/min)

Severe hepatic impairment

Inflammatory bowel disease

Gastroparesis

Cancer

Chronic obstructive lung disease

Psychiatric disease, a history of major depressive or other severe psychiatric disorders

Bleeding diathesis or anticoagulant treatment

Current or history of neurological disease including traumatic brain injury

Contraindications for MR scanning (implants, claustrophobia, etc.)

The use of medications that cause clinically significant weight gain or loss

Previous bariatric surgery

A history of idiopathic acute pancreatitis

A family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma

Current smoking

Pregnancy, expecting pregnancy or breastfeeding

Allergy to any of the ingredients of the study medication: semaglutide, disodium phosphate dihydrate, propylene glycol, phenol, hydrochloric acid and sodium hydroxide

Anticipated change in lifestyle (e.g. eating, exercise or sleeping pattern) during the trial

Any condition that the investigator feels would interfere with trial participation (such as inability to follow frequent trial visits according to protocol schedule)

  1. Abbreviations: PCOS polycystic ovary syndrome, BMI body mass index, GFR glomerular filtration rate, MR scanning magnetic resonance scanning